Investigation of the clinical efficacy and safety of herbal Algan Hemostatic Agent in coronary artery bypass graft surgery

Abstract

Background. Hemostatic agents have the potential to improve clinical outcomes by decreasing postoperative drainage and the need for transfusions. Algan Hemostatic Agent is a polysaccharide-based hemostatic agent obtained from a mixture of six different herbs. The aim of this study is to investigate the clinical efficacy and safety of Algan Hemostatic Agent as a local hemostatic agent in coronary artery bypass operations. Methods. 28 subjects who underwent isolated coronary artery bypass graft surgery and met the inclusion criteria were included in this clinical study. Traditional methods (cautery, ligation, etc.) were used in the control group, whereas Algan Hemostatic Agent was added in the study group. A sponge soaked in Algan Hemostatic Agent liquid was lightly compressed to the bleeding area for 120 seconds. Results. Both groups were comparable in terms of preoperative demographic data and perioperative laboratory values. Drainage on the postoperative first day (650 ml vs 896 ml; p=0.381) and total drainage (817 ml vs 1210 ml; p=0.031) were found higher in the control group. Another significant difference was observed between the groups in terms of erythrocyte suspension utilization rate (1.14 U in the treatment group and 2.06 U in the control group, p=0.004). Algan Hemostatic Agent did not cause any complications during administration. Conclusion. In conclusion, Algan Hemostatic Agent has been found effective and safe in controlling bleeding during coronary artery bypass operations.